CY1105380T1 - Προτιμωμενα τμηματα της νευρικης νηματικης πρωτεϊνης και μεθοδοι χρησης αυτων - Google Patents

Προτιμωμενα τμηματα της νευρικης νηματικης πρωτεϊνης και μεθοδοι χρησης αυτων

Info

Publication number
CY1105380T1
CY1105380T1 CY20061101300T CY061101300T CY1105380T1 CY 1105380 T1 CY1105380 T1 CY 1105380T1 CY 20061101300 T CY20061101300 T CY 20061101300T CY 061101300 T CY061101300 T CY 061101300T CY 1105380 T1 CY1105380 T1 CY 1105380T1
Authority
CY
Cyprus
Prior art keywords
methods
preferred
filament protein
protein portions
preferred neural
Prior art date
Application number
CY20061101300T
Other languages
English (en)
Inventor
Judith Fitzpatrick
Paul Averback
Ma. Soledad S. Focht
Riza Bibiano
Original Assignee
Nymox Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Pharmaceutical Corporation filed Critical Nymox Pharmaceutical Corporation
Publication of CY1105380T1 publication Critical patent/CY1105380T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Η εφεύρεση απευθύνεται σε προτιμώμενες επαναλαμβανόμενες αλληλουχίες της Νευρικής Νηματικής Πρωτεΐνης (ΝΤΡ), πεπτίδια, μιμητικά, αντισώματα, και πυρηνικά οξέα των προτιμώμενων αλληλουχιών, και διαγνωστικές και θεραπευτικές μέθοδοι χρήσης αυτών των προτιμώμενων αλληλουχιών ΝΤΡ.
CY20061101300T 2000-10-27 2006-09-12 Προτιμωμενα τμηματα της νευρικης νηματικης πρωτεϊνης και μεθοδοι χρησης αυτων CY1105380T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/697,590 US7259232B1 (en) 2000-10-27 2000-10-27 Preferred segments of neural thread protein
PCT/US2001/042813 WO2002034915A2 (en) 2000-10-27 2001-10-25 Preferred segments of neural thread protein and methods of using the same

Publications (1)

Publication Number Publication Date
CY1105380T1 true CY1105380T1 (el) 2010-04-28

Family

ID=24801714

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101300T CY1105380T1 (el) 2000-10-27 2006-09-12 Προτιμωμενα τμηματα της νευρικης νηματικης πρωτεϊνης και μεθοδοι χρησης αυτων

Country Status (15)

Country Link
US (2) US7259232B1 (el)
EP (2) EP1702985A3 (el)
JP (1) JP2005512500A (el)
KR (1) KR100843792B1 (el)
CN (1) CN1492926A (el)
AT (1) ATE330011T1 (el)
AU (1) AU2002232392A1 (el)
BR (1) BR0114977A (el)
CA (1) CA2427070A1 (el)
CY (1) CY1105380T1 (el)
DE (1) DE60120782T2 (el)
DK (1) DK1379650T3 (el)
ES (1) ES2266296T3 (el)
PT (1) PT1379650E (el)
WO (1) WO2002034915A2 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002302239B2 (en) * 2000-10-27 2006-12-14 Nymox Corporation Method of preventing cell death using segments of neural thread proteins
CA2446945A1 (en) 2001-05-16 2002-11-21 Nymox Corporation Method of preventing cell death using segments of neural thread proteins
EP1541166B1 (en) * 2001-05-16 2007-12-19 Nymox Corporation Preventing cell death using segments of neural thread proteins
DE60217326T2 (de) 2001-05-25 2007-10-18 Nymox Corp., Saint-Laurent Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung
US7544771B2 (en) * 2005-02-23 2009-06-09 Nymox Corporation Protein and its use in diagnosing Alzheimer's disease
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) * 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068375A3 (en) 1981-06-22 1983-04-13 G.D. Searle & Co. Recombinant dna techniques for the production of relaxin
SE8300693L (sv) 1983-02-09 1984-08-10 Sven Lofdahl Sett att framstella och isolera proteiner och polypeptider samt en hybridvektor for detta
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5084559A (en) 1987-03-27 1992-01-28 Repligen Corporation Protein a domain mutants
US5948634A (en) 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
EP0378924B1 (en) 1988-12-21 1996-11-13 The General Hospital Corporation Detection of neurological disease or dysfunction
US5556781A (en) * 1994-03-07 1996-09-17 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo DNA encoding enzyme, recombinant DNA and enzyme, transformant, and their preparations and uses
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
US5958416A (en) 1994-12-16 1999-09-28 Regents Of The University Of Minnesota Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
US6610506B1 (en) * 1995-12-01 2003-08-26 University Technologies International, Inc. Transferrin binding proteins of Pasteurella haemolytica and vaccines containing same
US6013763A (en) 1996-06-04 2000-01-11 Genentech, Inc. Peptide variants of protein A
JP2001518455A (ja) 1997-09-30 2001-10-16 セル−サイ・コーポレーシヨン 単純疱疹ウイルスの処置のための免疫原性の複合ポリペプチド
US6399075B1 (en) 1998-07-02 2002-06-04 President And Fellows Of Harvard College Compositions and methods for treating Papillomavirus-infected cells
CA2364630A1 (en) 1999-03-12 2000-09-21 Human Genome Sciences, Inc. 50 human secreted proteins
AU3769700A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. 45 human secreted proteins
CA2446945A1 (en) 2001-05-16 2002-11-21 Nymox Corporation Method of preventing cell death using segments of neural thread proteins

Also Published As

Publication number Publication date
ES2266296T3 (es) 2007-03-01
EP1379650A2 (en) 2004-01-14
WO2002034915A3 (en) 2003-11-20
WO2002034915A2 (en) 2002-05-02
KR100843792B1 (ko) 2008-07-03
PT1379650E (pt) 2006-10-31
EP1702985A2 (en) 2006-09-20
DK1379650T3 (da) 2006-10-23
AU2002232392A1 (en) 2002-05-06
CN1492926A (zh) 2004-04-28
CA2427070A1 (en) 2002-05-02
EP1379650B1 (en) 2006-06-14
JP2005512500A (ja) 2005-05-12
KR20030067681A (ko) 2003-08-14
ATE330011T1 (de) 2006-07-15
US7259232B1 (en) 2007-08-21
US20090258426A1 (en) 2009-10-15
DE60120782D1 (de) 2006-07-27
DE60120782T2 (de) 2007-05-24
EP1702985A3 (en) 2007-03-07
BR0114977A (pt) 2006-05-09

Similar Documents

Publication Publication Date Title
CY1105380T1 (el) Προτιμωμενα τμηματα της νευρικης νηματικης πρωτεϊνης και μεθοδοι χρησης αυτων
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
CY1110571T1 (el) Επιλεκτικα μεσα δεσμευσης της ανθρωπινης αγγειοποιητινης-2
CY1110923T1 (el) Συζυγη που περιλαμβανουν ενα αντισωμα ειδικο για την ed-β περιοχη της ινονεκτινης και η χρηση τους για τον εντοπισμο και την αντιμετωπιση ογκων
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
CY1110634T1 (el) Μεθοδοι προληψης και θεραπειας της νοσου του αλτσχαϊμερ (ad)
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
CY1110679T1 (el) Νουκλεοτιδικες και πρωτεϊνικες ακολουθιες γονιδιων nogo και μεθοδοι βασιζομενες σε αυτες
ATE461938T1 (de) Mit entzündlichen darmerkrankungen (ibd) assoziierte mikrobielle antigene und verfahren derer anwendung
CY1115634T1 (el) Μεσα ανταγωνιστικης επιλεκτικης συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
ATE415423T1 (de) Immunisierungstherapie zur behandlung von atherosklerose
ES2333598T5 (es) Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
AR033978A1 (es) Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas
CY1107944T1 (el) Χρησεις του μπορρελιοκτονου επιτοπου (-ων) της πρωτεϊνης c εξωτερικης επιφανειας borrelia burgdorferi (ospc) σαν εμβολιο
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα
CY1109221T1 (el) Χιμαιρικο γονιδιο που κωδικοποιει τους αντιγονικους καθοριστες τεσσαρων πρωτεϊνων του l. infantum
PE20050962A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
DK1536006T3 (da) Cancerantigener og anvendelse deraf
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE356207T1 (de) Humanes btrcp protein